The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Asacolon     5-amino-2-hydroxy-benzoic acid

Synonyms: Salofalk, Ascolitin, Claversal, Lixacol, Mesasal, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of mesalamine


Psychiatry related information on mesalamine


High impact information on mesalamine


Chemical compound and disease context of mesalamine


Biological context of mesalamine


Anatomical context of mesalamine


Associations of mesalamine with other chemical compounds


Gene context of mesalamine


Analytical, diagnostic and therapeutic context of mesalamine


  1. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M. N. Engl. J. Med. (1987) [Pubmed]
  2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. Thomsen, O.O., Cortot, A., Jewell, D., Wright, J.P., Winter, T., Veloso, F.T., Vatn, M., Persson, T., Pettersson, E. N. Engl. J. Med. (1998) [Pubmed]
  3. Transdermal nicotine as maintenance therapy for ulcerative colitis. Thomas, G.A., Rhodes, J., Mani, V., Williams, G.T., Newcombe, R.G., Russell, M.A., Feyerabend, C. N. Engl. J. Med. (1995) [Pubmed]
  4. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. Miglioli, M., Barbara, L., Di Febo, G., Gozzetti, G., Lauri, A., Paganelli, G.M., Poggioli, G., Santucci, R. N. Engl. J. Med. (1989) [Pubmed]
  5. Diarrhea associated with mesalamine in a patient with chronic nongranulomatous enterocolitis. Fine, K.D., Sarles, H.E., Cryer, B. N. Engl. J. Med. (1998) [Pubmed]
  6. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Safdi, M., DeMicco, M., Sninsky, C., Banks, P., Wruble, L., Deren, J., Koval, G., Nichols, T., Targan, S., Fleishman, C., Wiita, B. Am. J. Gastroenterol. (1997) [Pubmed]
  7. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. Raedler, A., Behrens, C., Bias, P. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  8. Beneficial effects of ropivacaine in rat experimental colitis. Martinsson, T., Ljung, T., Rubio, C., Hellström, P.M. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  9. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G.C., Chavatte, P., Farce, A., Bulois, P., Cortot, A., Colombel, J.F., Desreumaux, P. J. Exp. Med. (2005) [Pubmed]
  10. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. Wahl, C., Liptay, S., Adler, G., Schmid, R.M. J. Clin. Invest. (1998) [Pubmed]
  11. Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitis. Santucci, L., Wallace, J., Mencarelli, A., Farneti, S., Morelli, A., Fiorucci, S. Gastroenterology (2005) [Pubmed]
  12. 5-Aminosalicylic acid protects against ischemia/reperfusion-induced gastric bleeding in the rat. Kvietys, P.R., Smith, S.M., Grisham, M.B., Manci, E.A. Gastroenterology (1988) [Pubmed]
  13. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Courtney, M.G., Nunes, D.P., Bergin, C.F., O'Driscoll, M., Trimble, V., Keeling, P.W., Weir, D.G. Lancet (1992) [Pubmed]
  14. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Green, J.R., Lobo, A.J., Holdsworth, C.D., Leicester, R.J., Gibson, J.A., Kerr, G.D., Hodgson, H.J., Parkins, K.J., Taylor, M.D. Gastroenterology (1998) [Pubmed]
  15. Mechanisms of carrageenan injury of IEC18 small intestinal epithelial cell monolayers. Ling, K.Y., Bhalla, D., Hollander, D. Gastroenterology (1988) [Pubmed]
  16. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Ardizzone, S., Maconi, G., Sampietro, G.M., Russo, A., Radice, E., Colombo, E., Imbesi, V., Molteni, M., Danelli, P.G., Taschieri, A.M., Bianchi Porro, G. Gastroenterology (2004) [Pubmed]
  17. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Allgayer, H., Ahnfelt, N.O., Kruis, W., Klotz, U., Frank-Holmberg, K., Söderberg, H.N., Paumgartner, G. Gastroenterology (1989) [Pubmed]
  18. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Rasmussen, S.N., Bondesen, S., Hvidberg, E.F., Hansen, S.H., Binder, V., Halskov, S., Flachs, H. Gastroenterology (1982) [Pubmed]
  19. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Sandoval, M., Liu, X., Mannick, E.E., Clark, D.A., Miller, M.J. Gastroenterology (1997) [Pubmed]
  20. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Lauritsen, K., Hansen, J., Ryde, M., Rask-Madsen, J. Gastroenterology (1984) [Pubmed]
  21. Delivery and fate of oral mesalamine microgranules within the human small intestine. Layer, P.H., Goebell, H., Keller, J., Dignass, A., Klotz, U. Gastroenterology (1995) [Pubmed]
  22. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Schreiber, S., MacDermott, R.P., Raedler, A., Pinnau, R., Bertovich, M.J., Nash, G.S. Gastroenterology (1991) [Pubmed]
  23. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Mulder, C.J., Tytgat, G.N., Weterman, I.T., Dekker, W., Blok, P., Schrijver, M., van der Heide, H. Gastroenterology (1988) [Pubmed]
  24. Inhibition of antibody secretion by 5-aminosalicylic acid. MacDermott, R.P., Schloemann, S.R., Bertovich, M.J., Nash, G.S., Peters, M., Stenson, W.F. Gastroenterology (1989) [Pubmed]
  25. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Lauritsen, K., Staerk Laursen, L., Bukhave, K., Rask-Madsen, J. Gut (1988) [Pubmed]
  26. Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. Yan, F., Polk, D.B. J. Biol. Chem. (1999) [Pubmed]
  27. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Schwab, M., Klotz, U. Clinical pharmacokinetics. (2001) [Pubmed]
  28. Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells. Estrada-Rodgers, L., Levy, G.N., Weber, W.W. Drug Metab. Dispos. (1998) [Pubmed]
  29. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Haskó, G., Szabó, C., Németh, Z.H., Deitch, E.A. Immunology (2001) [Pubmed]
  30. The effect of second-line antirheumatic drugs on interleukin-8 mRNA synthesis and protein secretion in human endothelial cells. Deleuran, B., Kristensen, M., Paludan, K., Zachariae, C., Larsen, C.G., Zachariae, E., Thestrup-Pedersen, K. Cytokine (1992) [Pubmed]
  31. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Kamm, M.A., Sandborn, W.J., Gassull, M., Schreiber, S., Jackowski, L., Butler, T., Lyne, A., Stephenson, D., Palmen, M., Joseph, R.E. Gastroenterology (2007) [Pubmed]
  32. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Cammà, C., Giunta, M., Rosselli, M., Cottone, M. Gastroenterology (1997) [Pubmed]
  33. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Wallace, J.L., MacNaughton, W.K., Morris, G.P., Beck, P.L. Gastroenterology (1989) [Pubmed]
WikiGenes - Universities